# Formulation Development and Clinical Manufacturing: Manufacture of TLC-ART101 Bulk Product for Clinical Trials

> **NIH NIH N01** · SRI INTERNATIONAL · 2020 · $785,631

## Abstract

The Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), maintains a portfolio of contracts to support the development of (1) therapies for HIV infection and its complications and coinfections, and (2) microbicides for preventing the sexual transmission of HIV. Services provided under this contract assist investigators in academic settings and small pharmaceutical firms in filling specific gaps in their drug development plan as they advance their product towards clinical investigation of therapies for HIV infection and interventions to prevent HIV transmission. Activities will include the development of formulations of potential therapeutic agents and microbicides. In addition studies will be conducted to assess the pharmacology and toxicology of potential therapeutic agents and microbicides.

## Key facts

- **NIH application ID:** 10215314
- **Project number:** 272201400006I-0-759302000001-1
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** JON MIRSALIS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $785,631
- **Award type:** —
- **Project period:** 2020-07-15 → 2021-07-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10215314

## Citation

> US National Institutes of Health, RePORTER application 10215314, Formulation Development and Clinical Manufacturing: Manufacture of TLC-ART101 Bulk Product for Clinical Trials (272201400006I-0-759302000001-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10215314. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*